Aortyx, a spin-off of the IQS School of Engineering and Hospital Clinic Barcelona that specialises in creating endovascular devices for aortic dissections, has increased its capital by €650,000 in a round led by Genesis Ventures.

“This investment will allow us to continue meeting the deadlines we’ve set and moving towards our goal of launching the best possible product to market,” says Dr Jordi Martorell, co-founder and CEO of Aortyx.

The company has begun animal studies and will start industrialisation of its medical device with the goal of marketing it by 2024.

Both Aortyx and Genesis Ventures are CataloniaBio & HealthTech members.

You may also be interested in: 

Aortyx awarded Neotec grant for €250,000

Want to learn more about what Aortyx does? We recommend this video interview: